Association of the Progesterone receptor gene with breast cancer risk: A single-nucleotide polymorphism tagging approach

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 4, 2006, Pages 675-682

  Pooley, Karen A ^a,b   Healey, Catherine S ^a   Smith, Paula L ^b   Pharoah, Paul D P ^a   Thompson, Deborah ^b   Tee, Louise ^a,c   West, Judith ^a   Jordan, Clare ^a   Easton, Douglas F ^b   Ponder, Bruce A J ^a   Dunning, Alison M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LEUCINE; PROGESTERONE RECEPTOR; VALINE;

ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; GENETIC HETEROGENEITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GREAT BRITAIN; HAPLOTYPES; HUMANS; LINKAGE DISEQUILIBRIUM; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, PROGESTERONE; RISK; SEQUENCE TAGGED SITES; VALINE;

EID: 33646252498     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0679     Document Type: Article

References (46)

1. Lydon JP, DeMayo FJ, Funk CR, et al. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev 1995;9:2266-78.
2. Westberg L, Ho HP, Baghaei F, et al. Polymorphisms in oestrogen and progesterone receptor genes: possible influence on prolactin levels in women. Clin Endocrinol (Oxf) 2004;61:216-23.
3. Cheon YP, Li Q, Xu X, et al. A genomic approach to identify novel progesterone receptor regulated pathways in the uterus during implantation. Mol Endocrinol 2002;16:2853-71.
4. Williams SP, Sigler PB. Atomic structure of progesterone complexed with its receptor. Nature 1998;393:392-6.
5. Musgrove EA, Lee CS, Sutherland RL. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor a, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol 1991;11:5032-43.
6. Deming SL, Nass SJ, Dickson RB, et al. C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer 2000; 83:1688-95.
7. Gabra H, Taylor L, Cohen BB, et al. Chromosome 11 allele imbalance and clinicopathological correlates in ovarian tumours. Br J Cancer 1995;72: 367-75.
8. Winqvist R, Hampton GM, Mannermaa A, et al. Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis. Cancer Res 1995;55:2660-4.
9. Hampton GM, Mannermaa A, Winqvist R, et al. Loss of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3. Cancer Res 1994;54:4586-9.
10. Micheli A, Muti P, Secreto G, et al. Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int J Cancer 2004; 112:312-8.
11. Chappell PE, Lydon JP, Conneely OM, et al. Endocrine defects in mice carrying a null mutation for the progesterone receptor gene. Endocrinology 1997;138:4147-52.
12. Stierer M, Rosen H, Weber R, et al. Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Correlation of histopathology and prognostic factors. Ann Surg 1993; 218:13-21.
13. Mohsin SK, Weiss H, Havighurst T, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol 2004;17:1545-54.
14. Bernoux A, de Cremoux P, Laine-Bidron C, et al. Estrogen receptor negative and progesterone receptor positive primary breast cancer: pathological characteristics and clinical outcome. Institut Curie Breast Cancer Study Group. Breast Cancer Res Treat 1998;49:219-25.
15. Nagai MA, Da Ros N, Neto MM, et al. Gene expression profiles in breast tumors regarding the presence or absence of estrogen and progesterone receptors. Int J Cancer 2004;111:892-9.
16. Sartorius CA, Melville MY, Hovland AR, et al. A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform. Mol Endocrinol 1994;8: 1347-60.
17. Conneely OM, Jericevic BM, Lydon JP. Progesterone receptors in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 2003;8:205-14.
18. Mulac-Jericevic B, Lydon JP, DeMayo FJ, et al. Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc Natl Acad Sci U S A 2003;100:9744-9.
19. De Vivo I, Hankinson SE, Colditz GA, et al. A functional polymorphism in the progesterone receptor gene is associated with an increase in breast cancer risk. Cancer Res 2003;63:5236-38.
20. Feigelson HS, Rodriguez C, Jacobs EJ, et al. No association between the progesterone receptor gene +331G>A polymorphism and breast cancer. Cancer Epidemiol Biomarkers Prev 2004;13:1084-5.
21. De Vivo I, Huggins GS, Hankinson SE, et al. A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc Natl Acad Sci U S A 2002;99:12263-8.
22. Berchuck A, Schildkraut JM, Wenham RM, et al. Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. Cancer Epidemiol Biomarkers Prev 2004;13:2141-7.
23. Cramer DW, Hornstein MD, McShane P, et al. Human progesterone receptor polymorphisms and implantation failure during in vitro fertilization. Am J Obstet Gynecol 2003;189:1085-92.
24. McKenna NJ, Kieback DG, Carney DN, et al. A germline TaqI restriction fragment length polymorphism in the progesterone receptor gene in ovarian carcinoma. Br J Cancer 1995;71:451-5.
25. Wang-Gohrke S, Chang-Claude J, Becher H, et al. Progesterone receptor gene polymorphism is associated with decreased risk for breast cancer by age 50. Cancer Res 2000;60:2348-50.
26. Dunning AM, Healey CS, Pharoah PD, et al. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1999;8:843-54.
27. Rowe SM, Coughlan SJ, McKenna NJ, et al. Ovarian carcinoma-associated Taq1 restriction fragment length polymorphism in intron G of the progesterone receptor gene is due to an Alu sequence insertion. Cancer Res 1995;55:2743-5.
28. Lattuada D, Somigliana E, Vigano P, et al. Genetics of endometriosis: a role for the progesterone receptor gene polymorphism PROGINS? Clin Endocrinol (Oxf) 2004;61:190-4.
29. Manolitsas TP, Englefield P, Eccles DM, et al. No association of a 306-bp insertion polymorphism in the progesterone receptor gene with ovarian and breast cancer. Br J Cancer 1997;75:1398-9.
30. Tong D, Fabjani G, Heinze G, et al. Analysis of the human progesterone receptor gene polymorphism progins in Austrian ovarian carcinoma patients. Int J Cancer 2001;95:394-7.
31. Fabjani G, Tong D, Czerwenka K, et al. Human progesterone receptor gene polymorphism PROGINS and risk for breast cancer in Austrian women. Breast Cancer Res Treat 2002;72:131-7.
32. 660Leu G/T polymorphism and risk of breast cancer in Australian women. Cancer Epidemiol Biomarkers Prev 2002;11:439-43.
33. De Vivo I, Hankinson SE, Colditz GA, et al. The progesterone receptor Val660→Leu polymorphism and breast cancer risk. Breast Cancer Res 2004;6:R636-9.
34. Gold B, Kalush F, Bergeron J, et al. Estrogen receptor genotypes and haplotypes associated with breast cancer risk. Cancer Res 2004;64:8891-900.
35. 660Leu G/T polymorphism and risk of ovarian cancer. Carcinogenesis 2001;22:717-21.
36. Pearce CL, Hirschhorn JN, Wu AH, et al. Clarifying the PROGINS allele association in ovarian and breast cancer risk: a haplotype-based analysis. J Natl Cancer Inst 2005;97:51-9.
37. Schweikert A, Rau T, Berkholz A, et al. Association of progesterone receptor polymorphism with recurrent abortions. Eur J Obstet Gynecol Reprod Biol 2004;113:67-72.
38. Day N, Oakes S, Luben R, et al. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer 1999;80 Suppl 1:95-103.
39. Satagopan JM, Verbel DA, Venkatraman ES, et al. Two-stage designs for gene-disease association studies. Biometrics 2002;58:163-70.
40. Satagopan JM, Elston RC. Optimal two-stage genotyping in population-based association studies. Genet Epidemiol 2003;25:149-57.
41. Satagopan JM, Venkatraman ES, Begg CB. Two-stage designs for gene-disease association studies with sample size constraints. Biometrics 2004; 60:589-97.
42. Abecasis GR, Cookson WO. GOLD - graphical overview of linkage disequilibrium. Bioinformatics 2000;16:182-3.
43. Stram DO, Haiman CA, Hirschhorn JN, et al. Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study. Hum Hered 2003;55:27-36.
44. Schaid DJ, Rowland CM, Tines DE, et al. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-34.
45. Conde L, Vaquerizas JM, Santoyo J, et al. PupaSNP Finder: a web tool for finding SNPs with putative effect at transcriptional level. Nucleic Acids Res 2004;32(Web Server issue):W242-8.
46. Pharoah PD, Dunning AM, Ponder BA, et al. The reliable identification of disease-gene associations. Cancer Epidemiol Biomarkers Prev 2005;14:1362.